Table 1.
Patient and treatment characteristics.
| TACE | SBRT | p-value* | |
|---|---|---|---|
| A. PATIENT CHARACTERISTICS | |||
| Age | 0.36 | ||
| median (range) | 69 (45–92) | 76 (58–85) | |
| Gender | |||
| Male | 18 (95%) | 13 (72%) | 0.09 |
| Female | 1 (5.3%) | 5 (28%) | |
| Etiology of liver disease | 0.74 | ||
| HBV | 2 (11%) | 4 (22%) | |
| HCV | 5 (23%) | 5 (28%) | |
| Alcohol induced | 2 (11%) | 6 (33%) | |
| NASH | 2 (11%) | 1 (6%) | |
| n.a. | 8 (42%) | 2 (11%) | |
| Treatments before study inclusion† | 0.19** | ||
| Resection | 0 (0%) | 4 (22%) | |
| RFA | 2 (11%) | 0 (0%) | |
| TACE | 7 (26%) | 11 (61%) | |
| SBRT | 0 (0%) | 1 (6%) | |
| Sorafenib, regorafenib | 0 (0%) | 0 (0%) | |
| SIRT | 0 (0%) | 2 (11%) | |
| No prior treatments | 12 (63%) | 7 (39%) | |
| Further treatments after study inclusion† | 0.6 | ||
| Resection | 1 (5%) | 0 (0%) | |
| Transplantation | 1 (5%) | 0 (0%) | |
| TACE | 6 (32%) | 2 (11%) | |
| SBRT | 2 (11%) | 3 (17%) | |
| Sorafenib, regorafenib | 2 (11%) | 5 (28%) | |
| SIRT | 0 (0%) | 1 (6%) | |
| No further treatments | 9 (47%) | 10(56%) | |
| BCLC | 0.0013 | ||
| A | 7 (37%) | 2 (11%) | |
| B | 12 (63%) | 7 (40%) | |
| C | 0 (0%) | 9 (50%) | |
| D | 0 (0%) | 0 (0%) | |
| Metastatic disease | 0 (0%) | 3 (17%) | 0.10 |
| Child pugh score baseline | 0.40*** | ||
| A | 17 (90%) | 14 (78%) | |
| 5 | 15 | 8 | |
| 6 | 2 | 6 | |
| B | 2 (10%) | 4 (22%) | |
| 7 | 1 | 2 | |
| 8 | 1 | 2 | |
| ALBI grade | 0.51 | ||
| 1 | 9 (47%) | 11(61%) | |
| 2 | 10 (53%) | 7 (40%) | |
| 3 | 0 (0%) | 0 (0%) | |
| Maximal tumor diameter (median, range), mm | 32 (10–78) | 42 (21–210) | 0.08 |
| Portal vein thrombosis (PVT) | 0 (0%) | 6 (37%) | 0.01 |
| B. TREATMENT CHARACTERISTICS | |||
| cTACE | 8 (42%) | ||
| Drug-eluting beads TACE | 11 (58%) | ||
| Total number of TACE sessions | |||
| One TACE | 6 (32%) | ||
| Two TACE | 7 (37%) | ||
| Three TACE | 2 (11%) | ||
| Five TACE | 1 (5%) | ||
| Six TACE | 1 (5%) | ||
| SBRT | |||
| Total prescribed dose, median (IQR) | 55 (49–60) Gy | ||
| BED10, median (IQR) | 100 (75–139) Gy | ||
| Dose per fraction, median (IQR) | 7.2 (5–15.9) Gy | ||
| Nr of fractions, median (IQR) | 5 (3–12) | ||
cTACE, conventional transarterial chemoembolization; BED, biological effective dose; NASH, non -alcoholic steatohepatitis; BCLC, Barcelona Clinic Liver Cancer; TACE, trans-arterial chemoembolization; PVT, portal vein thrombosis; SBRT, stereotactic body radiation therapy; cTACE, conventional transarterial chemoembolization;
*
Fisher's exact test (binary variables) or Wilcoxon's two-sample test (continuous variables);
**
yes vs. no prior treatment;
***
A vs. B; n.a, not available.
†
some patients received multiple treatments.